| Expression pattern: |
UP |
| Associated gene: |
FGF9, USF1 |
| Associated microRNA: |
miR-589-3p |
| Biological function: |
Promotes oxaliplatin resistance and reduces oxaliplatin-induced apoptosis in colorectal cancer. |
| Molecular mechanism: |
USF1 transcriptionally activates circ76691; circ76691 transcriptionally downregulates and sponges miR-589-3p, leading to upregulation of FGF9 and inhibition of oxaliplatin-induced apoptosis. |
| Biological pathway or process: |
apoptosis (inhibits); chemoresistance (promotes); ceRNA regulation (promotes); MAPK (other); PI3K/AKT (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Annexin V/PI Flow Cytometry; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry); ChIP / ChIP-seq; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circ76691 expression is higher in oxaliplatin-resistant CRC tissues and predicts poor outcome/shorter DFS; it is an independent risk factor for recurrence. |
| Description: |
hsa_circ_0076691 (circ76691), derived from RUNX2, is upregulated in oxaliplatin-resistant CRC cells and patient tumors. It promotes oxaliplatin resistance by inhibiting apoptosis via transcriptional repression and sponging of miR-589-3p, thereby increasing FGF9 expression; its expression is activated by the transcription factor USF1 and is associated with poorer patient DFS. |
| Confidence score: |
0.8974 |